News

Catch up on coverage from the editors of Dermatology Times® who attended the annual ASDS Meeting.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses holistic medicine vs. western medicine for eczema treatment.

Patients saw improvements in the first-ever phase 3 trial of the blood therapy for the condition.

Saranya Wyles, MD, PhD, takes a closer look at skin aging, cellular senescence, and emerging regenerative medicine techniques at the 2022 Annual ASDS Meeting.

At the 2022 Annual ASDS Meeting, Mona Gohara, MD, highlights the importance of diversity, equity, and inclusion in the field of dermatology.

Mona Sadeghpour, MD, FAAD, chair of the State of Affairs Work Group of ASDSA, spoke at the American Society for Dermatologic Surgery Meeting about how dermatologists can stay involved in dermatologic advocacy.

Patricia Farris, MD, dermatologist from Metairie, Louisiana, discusses key pearls from her presentation at the American Society for Dermatologic Surgery (ASDS) Meeting.

Peter Lio, MD, talks about the difficulties and strategies used when treating patients with this common skin disorder.

How will new federal law affect lives and wallets of physicians?

This week's edition of the Mainstream Patient features stories about recommended acne solutions from dermatologists, Latinx-owned beauty brands, the latest skin care trend of "skin energy," and more.

Click to see a preview of what to expect this week.

ICYMI, this week we had stories about new study data on roflumilast foam for scalp and body psoriasis, dupilumab's FDA approval, the future of basal cell carcinoma treatment, and more.

Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses common skin conditions related to polycystic ovary syndrome.

Pulse Biosciences' new technology will treat sebaceous hyperplasia patients with Fitzpatrick skin types I-III.

Don’t click on links or attachments unless you’re sure they are legitimate.

ICYMI, this week we had stories about the role of precision medicine for managing melanoma, a debridement drug for severe pediatric burns, roflumilast cream phase 3 results, and an exclusive KOL interview.

Federal AHRQ offers starting point for reducing greenhouse gas emissions.

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

In this week’s Pointers with Dr Portela, the 208SkinDoc reviews a video of laser tattoo removal.

Arcutis Biotherapeutics’ roflumilast cream showed higher efficacy compared to vehicle in two phase 3 studies.

MediWound’s debridement drug will provide a safer non-surgical alternative to severe thermal burns for pediatric patients.

Patients prefer virtual appointments for common ailments, but question the quality of care.

ICYMI, this week we had stories about products to help manage acne, a case study on pediatric vitiligo, data results from a hidradenitis suppurativa clinical trial, BCC management, and more.

Will Kirby, DO, FAOCD, and Karan Lal, DO, FAAD, MS, talk about falling in love with medicine, the best dermatology advice ever received, and losing over 100 pounds.

Aerolase launches the Exci308 to help fight common skin conditions.

Organizations that focus on diversity, equity and inclusion are more productive and employees are more satisfied.

At a poster session at the Skin of Color Update meeting in New York City, a study looked at whether women of color thought they were well-represented when it comes to learning about skin aging and prevention.

At the Skin of Color Update 2022 meeting, Pearl Grimes, MD, shares her thoughts on the recent approval of ruxolitinib cream.

Medical experts use common set of criteria to diagnose disease.